Welcome

Welcome to the Carolina BioOncology Institute (CBI).  We are a cancer therapy and research institute.  Our staff are dedicated to advancing the field of cancer research by making available the latest developments in therapeutic options.  CBI has developed an early phase clinical trial program which represents the cutting edge in immunotherapy and personalized cancer options.  Additionally, CBI is the incubator for BioCytics, a research and development firm working to identify novel drug targets.  We are excited that you are considering a visit to our clinic and we look forward to providing you with the  most recent clinical trial options and the highest quality care.

 

 

Recent Clincial Trials

Protocol D419100003: A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736 (anti-PD-L1) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen

Sponsor: Astra Zeneca
Status: Open for recruitment
More Details

Protocol EMR 100070-001: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of an anti-PD-L1 antibody in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

Sponsor: Merck
Status: This study is currently recruiting participants.
More Details

Protocol GO28754: A Phase II, Multicenter, Single-Arm Study of MPDL3280A (anti-PD-L1) in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Roche-Genentech
Status: Recruiting patients now
More Details

Protocol IMC 1114: A Study to Determine Whether Necitumumab (IMC-11F8; anti-EGFR) Monotherapy Affects the Corrected QT (QTc) Interval in Subjects with Advanced Solid Tumors

Sponsor: ImClone
Status: This study is currently recruiting participants.
More Details

Protocol GP28328: A Phase IB Study of the Safety and Pharmacology of MPDL3280A (anti-PD-L1) Administered with Bevacizumab and/or Chemotherapy in Patients with Advanced Solid Tumors

Sponsor: Genentech
Status: This study is currently recruiting participants.
More Details

Protocol PCD4989g: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A (anti-PD-L1) Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors of Hematologic Malignancies

Sponsor: Genentech
Status: This study is currently recruiting participants.
More Details

Latest News

It’s Cancer Immunotherapy Month

June 2nd, 2014

June is Cancer Immunotherapy Month! If you haven’t heard about this yet, don’t worry, it’s only the second year of this awareness-raising event.  Carolina BioOncology Institute is proud to be on the cutting edge of cancer research by offering a number of immunological trials.  Immunologically-based drugs offer many advantages over standard chemotherapy, including the promise [...]

READ MORE

Immuno-Oncology Program

May 27th, 2014

Dr. Powderly is on the planning committee for “Tumor Immunology 101: A Navigation Guide for the New Field of Immuno-Oncology”, a program that covers the principles of tumor immunology and immunotherapy.  This one-day event to be held in Charlotte is for clinical oncologists, caregivers, patient advocates, and allied health professionals, as well as anyone who [...]

READ MORE

pad-pdf

9801 Kincey Ave,
Suite 145 Bostick Building
Huntersville, NC 28078

Get Directions

Social Updates